Dianthus Therapeutics Profit Margin

The latest profit margin for DNTH is -12.97% as of March 2026. That compares with -40.47% in the prior-year period — up 68.0% year over year. That is below the Healthcare sector average of 15.52%. Investors often review this figure alongside Dianthus Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, DNTH's profit margin moved from -40.47% to -12.97% — a 68.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Dianthus Therapeutics's valuation or profitability profile.

Against Healthcare companies, DNTH currently prints -12.97% for profit margin, while the sector average sits near 15.52%. That is roughly 8457.0% below the sector mean. Large gaps often invite a closer look at Dianthus Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Dianthus Therapeutics converts resources into returns. At -12.97%, DNTH may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -40.47% in the prior-year period — up 68.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting DNTH's profit margin (-12.97%), review year-over-year change from -40.47%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.